Literature DB >> 26377941

The Stress Kinase p38α as a Target for Cancer Therapy.

Ana Igea1, Angel R Nebreda2.   

Abstract

p38α is a ubiquitous protein kinase strongly activated by stress signals, inflammatory cytokines, and many other stimuli, which has been implicated in the modulation of multiple cellular processes. There is good evidence in the literature that p38α plays an important tumor-suppressor role by interfering with malignant cell transformation. This is mainly based on the ability of the p38α pathway to regulate tissue homeostasis by integrating signals that balance cell proliferation and differentiation or induce apoptosis. However, recent reports have also illustrated protumorigenic functions for p38α. Thus, p38α signaling may facilitate the survival and proliferation of tumor cells contributing to the progression of some tumor types. In addition, p38α activation helps tumor cells to survive chemotherapeutic treatments. In all these cases, the inhibition of p38α has a potential therapeutic interest. Further elucidation of the context-dependent functions of p38α signaling in tumoral processes is of obvious importance for the use of inhibitors of this pathway in cancer therapy. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26377941     DOI: 10.1158/0008-5472.CAN-15-0173

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  67 in total

1.  Role of Molecular Interactions and Protein Rearrangement in the Dissociation Kinetics of p38α MAP Kinase Type-I/II/III Inhibitors.

Authors:  Wanli You; Chia-En A Chang
Journal:  J Chem Inf Model       Date:  2018-04-16       Impact factor: 4.956

Review 2.  Regulation of senescence traits by MAPKs.

Authors:  Carlos Anerillas; Kotb Abdelmohsen; Myriam Gorospe
Journal:  Geroscience       Date:  2020-04-16       Impact factor: 7.713

3.  Potential Mean Force from Umbrella Sampling Simulations: What Can We Learn and What Is Missed?

Authors:  Wanli You; Zhiye Tang; Chia-En A Chang
Journal:  J Chem Theory Comput       Date:  2019-03-14       Impact factor: 6.006

4.  IGF2BP1: a novel binding protein of p38 MAPK.

Authors:  Jacob Rini; Moorthy Anbalagan
Journal:  Mol Cell Biochem       Date:  2017-05-11       Impact factor: 3.396

5.  Identification of Genes Regulating Breast Cancer Dormancy in 3D Bone Endosteal Niche Cultures.

Authors:  Julie McGrath; Louis Panzica; Ryan Ransom; Henry G Withers; Irwin H Gelman
Journal:  Mol Cancer Res       Date:  2019-01-16       Impact factor: 5.852

6.  Active p38α causes macrovesicular fatty liver in mice.

Authors:  Ilona Darlyuk-Saadon; Chen Bai; Chew Kiat Matthew Heng; Nechama Gilad; Wei-Ping Yu; Pei Yen Lim; Amaury Cazenave-Gassiot; Yongliang Zhang; W S Fred Wong; David Engelberg
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

Review 7.  P2Y1R and P2Y2R: potential molecular triggers in muscle regeneration.

Authors:  Min-Jia Wang; Bi-Ru Yang; Xin-Yu Jing; Yao-Zheng Wang; Lu Kang; Kai Ren; Liang Kang
Journal:  Purinergic Signal       Date:  2022-07-29       Impact factor: 3.950

Review 8.  Tumor cell vascular mimicry: Novel targeting opportunity in melanoma.

Authors:  Mary J C Hendrix; Elisabeth A Seftor; Richard E B Seftor; Jun-Tzu Chao; Du-Shieng Chien; Yi-Wen Chu
Journal:  Pharmacol Ther       Date:  2016-01-22       Impact factor: 12.310

9.  Requirement for epithelial p38α in KRAS-driven lung tumor progression.

Authors:  Jessica Vitos-Faleato; Sebastián M Real; Nuria Gutierrez-Prat; Alberto Villanueva; Elisabet Llonch; Matthias Drosten; Mariano Barbacid; Angel R Nebreda
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-22       Impact factor: 11.205

10.  Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model.

Authors:  Yoshio Shimizu; Takafumi Tamura; Akira Kemmochi; Yohei Owada; Yusuke Ozawa; Katsuji Hisakura; Takashi Matsuzaka; Hitoshi Shimano; Noriyuki Nakano; Shingo Sakashita; Tatsuya Oda; Nobuhiro Ohkohchi
Journal:  J Gastroenterol Hepatol       Date:  2020-10-05       Impact factor: 4.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.